Sanofi's Praluent, GSK's malaria vax up for CHMP backing this week; Novartis contends Lucentis more cost-effective than Eylea;

@FiercePharma: India's Torrent completes deal to buy family-run Zyg Pharma, gets FDA plant. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: ICYMI: Bayer homes in on €10B plastics IPO with plans for summer roadshow. Report | Follow @CarlyHFierce

> Sanofi ($SNY) and Regeneron's ($REGN) cholesterol drug Praluent and GlaxoSmithKline's ($GSK) malaria vaccine could win backing from E.U. regulators as soon as this week. Report

> Novartis ($NVS) says its eye drug Lucentis is more cost-effective than Bayer's Eylea for treating diabetic macular edema, in an analysis published in ClinicoEconomics and Outcomes Research. Report

> Baxter ($BAX) pulled two lots of its saline solution after a customer complaints about insect particles in the IV bags. Report

> Sun Pharma said its merger with Ranbaxy Laboratories would take a toll on its revenue and profits, partly because of the costs of integrating the two companies and fixing problems at Ranbaxy facilities. Report

> European officials approved CSL's buyout of Novartis' flu vaccines business. Report

Medical Device News

@FierceMedDev: Alere revs up engine with new deals and win for quick strep test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Indian stentmakers gaining global foothold--is U.S. market next? More | Follow @VarunSaxena2

@EmilyWFierce: Kim Kardashian speaks out for Duchesnay's morning sickness drug, Diclegis. FiercePharmaMarketing press release | Follow @EmilyWFierce

> Boston Scientific faces reimbursement hurdles for lung-searing asthma treatment. Story

> UCLA adopts startup cleaning system to help stop spread of superbugs via duodenoscopes. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Tekmira changes its name and shuffles away from Ebola. News | Follow @FierceBiotech

@JohnCFierce: ICYMI: Adaptimmune touts a promising snapshot of TCRs for myeloma. More | Follow @JohnCFierce

@DamianFierce: You can watch The Atlantic's AAIC2015-adjacent chat thing, ft. $LLY, here. | Follow @DamianFierce

> Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes. Item

> 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. More

> Athyrium debuts a $1.2B fund to bet on biopharmas. Article

Drug Delivery News

> Two oral therapeutics specialists bag a combined $140M via IPO, VC funding. Item

> Glucose delivery pathway that feeds tumors could be exploited to knock them down. More

> Minimally invasive brain probe uses light flashes to target drugs. Story

> Purdue team developing smart capsule for diseases of the large intestine. Report

> Novo to sell shield for concealing the needle of its injection pens. Article

Pharma Manufacturing News

> Biogen gets all of North Carolina site from Eisai as part of manufacturing build-out. Story

> Amgen's Colorado plant hits the market for $85M. Item

> Valeant gets manufacturing in Middle East with deal for Amoun. More

> Baxter IDs particulate in recalled saline as insects. Article

> AMRI picks up Spanish drugmaker in $174M deal. News

Pharma Asia News

> AdvaMed welcomes legislation to separate India's device and drug oversight. Item

> ASLAN and Singapore's NCCS plan studies on Asia-prevalent cancers. More

> India's Sun Pharma sees multiyear earnings hit as it fixes plants, integrates Ranbaxy. Report

> Medidata's de Vries on disruption in Asia drug research with Japan a focus. Story

> Singapore's biopharma industry: Where the jobs are. Article

And Finally... People at high risk of contracting HIV took their preventive meds--pre-exposure prophylaxis, or PrEP--mostly as directed in a new study; despite FDA approval to stave off HIV infection, Gilead Sciences' ($GILD) Truvada hasn't been widely adopted for that use. Release